Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | DRD3 | P35462 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.34 |
| ▸ | SYK | P43405 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | GRM5 | P41594 | 1/20 | 0.32 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22178978 | 0.83 | SMN1; SMN2 (0.56) | SMN1; SMN2HTTTP53KMT2AMEN1 | |
| SCHEMBL29542273 | 0.83 | SMN1; SMN2 (0.56) | SMN1; SMN2HTTTP53KMT2AMEN1 | |
| SCHEMBL28628281 | 0.80 | HTT (0.44) | SMN1; SMN2HTTKMT2AMEN1MAPT | |
| SCHEMBL28632463 | 0.78 | HTT (0.41) | SMN1; SMN2HTTKMT2AMEN1MAPT | |
| SCHEMBL22165488 | 0.73 | SMN1; SMN2 (0.62) | SMN1; SMN2HTTTP53KMT2AMEN1 | |
| SCHEMBL22165369 | 0.67 | SMN1; SMN2 (0.49) | SMN1; SMN2HTTTP53KMT2AMEN1 | |
| SCHEMBL22165818 | 0.67 | SMN1; SMN2 (0.49) | SMN1; SMN2HTTTP53KMT2AMEN1 | |
| SCHEMBL29541701 | 0.67 | SMN1; SMN2 (0.49) | SMN1; SMN2HTTTP53KMT2AMEN1 | |
| SCHEMBL30879292 | 0.64 | GAA (0.59) | SMN1; SMN2HTTKMT2AMEN1MAPT | |
| SCHEMBL5454456 | 0.63 | HTT (0.51) | SMN1; SMN2HTTTP53KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220098203-A1 | AZA-HETEROBICYCLIC INHIBITORS OF MAT2A AND METHODS OF USE FOR TREATING CANCER | LES LABORATOIRES SERVIER (FR) | 2022-03-31 | — | — | US | disclosed |
| EP-3902804-A1 | AZA-HETEROBICYCLIC INHIBITORS OF MAT2A AND METHODS OF USE FOR TREATING CANCER | Les Laboratoires Servier SAS (FR) | 2021-11-03 | — | — | EP | disclosed |
| WO-2020139992-A1 | AZA-HETEROBICYCLIC INHIBITORS OF MAT2A AND METHODS OF USE FOR TREATING CANCER | AGIOS PHARMACEUTICALS, INC. (US) | 2020-07-02 | — | — | WO | disclosed |
| WO-2020139992-A1 | AZA-HETEROBICYCLIC INHIBITORS OF MAT2A AND METHODS OF USE FOR TREATING CANCER | AGIOS PHARMACEUTICALS, INC. (US) | 2020-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220098203-A1 | AZA-HETEROBICYCLIC INHIBITORS OF MAT2A AND METHODS OF USE FOR TREATING CANCER | MAT2A, MAT2B, MAT1A | SMN1; SMN2 1525/4885HTT 3556/4885TP53 809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.